All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate … [Read more…]
BOSTON–(BUSINESS WIRE)–Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the closing of its previously announced upsized underwritten public offering of 4,011,628 shares of common stock, including the exercise in full by the underwriters of their option … [Read more…]
HALIFAX, Nova Scotia–(BUSINESS WIRE)–Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022. “As threats from both known and emerging infectious … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of … [Read more…]
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. Liquidity and Capital Resources During the first quarter of 2022, AgeX borrowed the final $0.5 million of its available credit under its 2020 … [Read more…]
SHORT HILLS, N.J.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022. “We have made excellent progress on the strategic realignment announced in July. We … [Read more…]
Vendors selected for the report are noteworthy, visionary, and innovative in their respective fields LOS ANGELES–(BUSINESS WIRE)–Pearl, the global leader in dental AI solutions, announced today that it has been included on the 2022 list of “Hot Vendors” in Computer Visioni by Aragon Research, Inc. The firm’s report identifies vendors whose technology provides transformative capabilities … [Read more…]
BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) relating to the parties’ 2008 collaboration agreement for the use of Seagen’s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Erosive Esophagitis – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This “Erosive Esophagitis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Erosive Esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Alopecia – Epidemiology Forecast to 2032” report has been added to ResearchAndMarkets.com’s offering. This “Alopecia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Alopecia Epidemiology … [Read more…]
